



Complete Summary

GUIDELINE TITLE

Urinary tract infection.

BIBLIOGRAPHIC SOURCE(S)

University of Michigan Health System. Urinary tract infection. Ann Arbor (MI): University of Michigan Health System; 2005 May. 9 p. [10 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: University of Michigan Health System. UMHS urinary tract infection guideline. Ann Arbor (MI): University of Michigan Health System; 1999 Jun. 7 p.

** REGULATORY ALERT **

FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse (NGC): This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

- [July 08, 2008, Fluoroquinolones \(ciprofloxacin, norfloxacin, ofloxacin, levofloxacin, moxifloxacin, gemifloxacin\)](#): A BOXED WARNING and Medication Guide are to be added to the prescribing information to strengthen existing warnings about the increased risk of developing tendinitis and tendon rupture in patients taking fluoroquinolones for systemic use.

COMPLETE SUMMARY CONTENT

** REGULATORY ALERT **
SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
CONTRAINDICATIONS
QUALIFYING STATEMENTS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES

SCOPE

DISEASE/CONDITION(S)

- Uncomplicated urinary tract infection
- Recurrent urinary tract infections
- Asymptomatic bacteriuria
- Acute uncomplicated pyelonephritis
- Urinary tract infection in pregnancy

GUIDELINE CATEGORY

Assessment of Therapeutic Effectiveness
Diagnosis
Evaluation
Management
Prevention
Treatment

CLINICAL SPECIALTY

Family Practice
Infectious Diseases
Internal Medicine
Nephrology
Nursing
Obstetrics and Gynecology
Urology

INTENDED USERS

Advanced Practice Nurses
Nurses
Physician Assistants
Physicians

GUIDELINE OBJECTIVE(S)

To implement a cost-effective strategy for uncomplicated urinary tract infection (UTI) in women

TARGET POPULATION

Adult women with uncomplicated urinary tract infection

INTERVENTIONS AND PRACTICES CONSIDERED

1. Diagnosis
 - Diagnosis based on symptoms and patient history
 - Phone triage
 - Laboratory diagnosis
 - Dipstick urinalysis for leukocyte esterase
 - Nitrite testing by dipstick
 - Microscopic examination of unstained, centrifuged urine under 40x power
 - Urine culture
 - Pelvic examination and physical exam
 - Urologic structural evaluation
2. Antibiotic treatment (trimethoprim/sulfamethoxazole [TMP/SMX]; quinolone [ciprofloxacin; levofloxacin]; amoxicillin; nitrofurantoin (Macrobid), cephalosporin)
 - Longer (7-10 day) courses of oral antibiotics
 - Shorter courses (3-5 days) of oral antibiotics
 - Single-course antibiotic regimen
 - Prolonged (2-6 weeks) courses of antibiotics
3. Follow-up urinalysis and urine cultures
4. Telephone triage and nurse-managed evaluation
5. Education of patients about reinfection
6. Prophylaxis and self initiated therapy

MAJOR OUTCOMES CONSIDERED

- Assessment of diagnostic tests (sensitivity, specificity, predictive value, validity)
- Response to treatment (cure rate, symptom relief)
- Drug side effects

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)
 Hand-searches of Published Literature (Secondary Sources)
 Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The literature search for this update began with the results of the literature search performed for the earlier version of this guideline. A search for literature published since that time was performed. The search was conducted prospectively on MEDLINE (U.S. National Library of Medicine) using the major keywords of: *urinary tract infections (including bacteriuria, pyuria, or schistosomiasis haematobia), guidelines, controlled trials, published from 7/1/98 to 8/31/04, and adult women.* Specific searches were performed for: *predictive value of tests, diagnosis (other than predictive value of tests), treatment, uncomplicated urinary tract infection (UTI) -- treatment, pregnancy, postmenopausal women -- treatment, recurrent UTI, self initiated therapy, group B strep and non-pregnant women, telephone triage -- nursing protocol, other treatment, other references to UTI.*

The search was conducted in components each keyed to a specific causal link in a formal problem structure (available upon request). The search was supplemented with recent clinical trials known to expert members of the panel. Negative trials were specifically sought. The search was a single cycle.

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Levels of evidence for the most significant recommendations:

- A. Randomized controlled trials
- B. Controlled trials, no randomization
- C. Observational trials
- D. Opinion of expert panel

METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Conclusions were based on prospective randomized clinical trials (RCTs) if available, to the exclusion of other data; if RCTs were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Consideration of benefits, harms, costs, and patient preferences

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

The guideline developers reviewed published cost-effectiveness studies. One study was a prospective randomized trial comparing the outcome of 3-day regimens of trimethoprim, sulfa, nitrofurantoin, cefadroxil and amoxicillin in women with cystitis. Trimethoprim/sulfa was shown to be more effective 80% (vs. <67%) and less expensive than the other regimens.

Another study, a before-and-after study with concurrent control groups at 24 primary care clinics to assess the effect of a telephone-based clinical practice guideline for managing presumed cystitis, was reviewed. Women 18 to 55 who met specific criteria were managed without a clinical visit or laboratory testing. Guideline use decreased laboratory utilization and overall costs while maintaining or improving the quality of care.

For more details, refer to the Annotated References section of the original guideline document.

METHOD OF GUIDELINE VALIDATION

Internal Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

University of Michigan Health System (UMHS) guidelines are reviewed by leadership and in clinical conferences of departments to which the content is most relevant. This guideline concerning urinary tract infection was reviewed by members of the following departments: General Medicine; Infectious Diseases; Family Practice; and Obstetrics & Gynecology.

Guidelines are approved by the Executive Committee of Clinical Affairs (ECCA).

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Note from National Guideline Clearinghouse (NGC): The following key points summarize the content of the guideline. Refer to the full text for additional information, including detailed information on diagnosis, treatment regimens and costs.

The levels of evidence [A-D] are defined at the end of the "Major Recommendations" field.

Diagnosis

- **History.** Diagnosis is made primarily by history. In women with dysuria and frequency, in the absence of vaginitis, the diagnosis is urinary tract infection (UTI) 80% of the time [C].
- **Phone triage.** In women with prior history of uncomplicated urinary tract infections (UTIs), consider phone triage [C].

- **Urinalysis.** Urinalysis for detection of pyuria by dipstick or microscope has a sensitivity of 80-90% and a specificity of 50% for predicting UTI [B].
- **No urine culture.** Urine culture is NOT indicated in the vast majority of UTIs. Urine culture (UC) has a sensitivity of 50% (if threshold for positive is $>10^5$ organisms); sensitivity can be increased to $>90\%$ if threshold is $>10^2$ organisms [C]. Consider urine culture only in recurrent UTI or in the presence of complicating factors.

Treatment

- **First line:** three days of trimethoprim/sulfa [A].
- **Second line:**
 - three days of quinolone (contraindicated in pregnancy) [A].
 - seven days of nitrofurantoin, amoxicillin, first-generation cephalosporin [A].

Follow-up

- **No tests if asymptomatic.** No laboratory follow-up is necessary if asymptomatic [B].
- **For recurrent UTIs.** In patients with recurrent UTIs (>3 /year):
 - consider prophylaxis/self-initiated therapy [A]
 - urologic structural evaluation rarely indicated [D]

Definitions:

Levels of evidence:

- A. Randomized controlled trials
- B. Controlled trials, no randomization
- C. Observational trials
- D. Opinion of expert panel

CLINICAL ALGORITHM(S)

An algorithm is provided in the original guideline document for the diagnosis and management of urinary tract infection (UTI).

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of evidence is identified and graded for the most significant recommendations (see "Major Recommendations").

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

- Clinical care resources are utilized appropriately and good clinical outcomes are obtained when a cost-effective strategy is used for the diagnosis and treatment of uncomplicated urinary tract infection.
- A review of 28 treatment trials of adult women with uncomplicated cystitis concluded that no benefit was achieved by increasing the length of therapy beyond 5 days. Specific benefits of shorter course (<5 days) antibiotic therapy include:
 - Decreased costs of antibiotics
 - Improved patient compliance
 - Decreased adverse effects of antibiotic treatments (e.g., amoxicillin-associated vaginitis)
- A recent study in Seattle examined a phone triage guideline. Use of the guideline decreased cost and increased appropriate antibiotic use without any increase in adverse outcomes.

POTENTIAL HARMS

Side effects of antibiotic treatment include rash, nausea, diarrhea, and vaginitis. Adverse effects associated with the use of trimethoprim/sulfamethoxazole (TMP/SMX) increase markedly if treatment is continued past 3 days.

CONTRAINDICATIONS

CONTRAINDICATIONS

Quinolones are contraindicated in pregnancy.

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgement regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

IMPLEMENTATION TOOLS

Clinical Algorithm
Patient Resources

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Living with Illness

IOM DOMAIN

Effectiveness
Patient-centeredness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

University of Michigan Health System. Urinary tract infection. Ann Arbor (MI): University of Michigan Health System; 2005 May. 9 p. [10 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1999 Jun (revised 2005 May)

GUIDELINE DEVELOPER(S)

University of Michigan Health System - Academic Institution

SOURCE(S) OF FUNDING

The University of Michigan Health System (UMHS) provides funding for guideline development. No external funds are used.

GUIDELINE COMMITTEE

Urinary Tract Infection Guideline Team

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Team Leader: Steven E. Gradwohl, MD, General Medicine

Team Members: Carol E. Chenoweth, MD, Infectious Diseases; Karen R. Fonde, MD, Family Practice; R. Van Harrison, PhD, Medical Education; Lauren B. Zoschnick, MD, Obstetrics & Gynecology

Guidelines Oversight Team: Connie J. Standiford, MD; Lee A. Green, MD, MPH; R. Van Harrison, PhD

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed. Disclosure of a relationship is not intended to suggest bias in the information presented, but is made to provide readers with information that might be of potential importance to their evaluation of the information.

Team Member; Company; Relationship

Carol E. Chenoweth, MD (None)

Karen R. Fonde, MD (None)

Steven E. Gradwohl, MD (None)

R. Van Harrison, PhD (None)

Lauren B. Zoschnick, MD (None)

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: University of Michigan Health System. UMHS urinary tract infection guideline. Ann Arbor (MI): University of Michigan Health System; 1999 Jun. 7 p.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the [University of Michigan Health System Web site](#).

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

The following is available:

- Urinary tract infection in women (UTI). University of Michigan Health System; 2005 Apr. Various p.

Electronic copies: Available from the [University of Michigan Health System Web site](#).

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC STATUS

This summary was completed by ECRI on August 21, 2000. The information was verified by the guideline developer on November 22, 2000. This summary was updated by ECRI on August 4, 2005. The updated information was verified by the guideline developer on August 10, 2005. This summary was updated by ECRI Institute on July 28, 2008 following the U.S. Food and Drug Administration advisory on fluoroquinolone antimicrobial drugs.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 11/10/2008

